
Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1
Keywords: Ponatinib; Endothelial-mesenchymal transition; Pulmonary arterial hypertension; FGF-2; VASH-2; VASH-1AP, Ponatinib; BLM, bleomycin; EndoMT, endothelial-mesenchymal transition; FGF-2, fibroblast growth factor; HE, hematoxylin and eosin; HPASMC, human pulmo